Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 3, 2008, Pages 117-121

  Xu, Feng Guo ^a   Zhang, Zun Jian ^a   Dong, Hai Juan ^a   Tian, Yuan ^a   Liu, Ying ^a   Chen, Yun ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b INSTITUTE OF DERMATOLOGY   (China)

Author keywords

Aldosterone antagonists; Antihypertensives; Canrenone, bioequivalence, pharmacokinetics; CAS 52 01 7; CAS 976 71 6; Spironolactone, bioequivalence, metabolite, pharmacokinetics

Indexed keywords

CANRENONE; ESTAZOLAM; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

EID: 41849139699     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296479     Document Type: Article

References (15)

1. Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther. 1986;9:63.
2. Rocco VK, Ware AJ. Cirrhotic ascites, pathophysiology, diagnosis, and management. Ann.Intern Med. 1986;105:573.
3. Skluth HA, Gums JG. Spironolactone: a re-examination. Drug Intell Clin Pharm. 1990;24:52.
4. Karim A, Hribar J, Aksamit W, Doherty M, Chinn LJ. Spironolactone metabolism in man studies by gaschromatography-mass spectrometry. Drug Metab Dispos. 1975;3:467.
5. Abshagen U, Rennekamp H. Isolation and identification of a sulfur-containing metabolite of spironolactone from human urine. Steroids. 1976;28:467.
6. Karim A, Zagarella I, Hutsell TC, Dooley M. Spironolactone III. Canrenone-maximum and minimum steady state plasma levels. Clin Pharmacol Ther. 1976;19:177.
7. The European Agency for the Evaluation of Medicinal Products Committee Proprietary Medical Pruducts. CPMP Note for Guidance of July 2001, CPMP/EWP/QWP/1401/98; the Investigation of Bioavailability and Bioequivalence.
8. Dong H, Xu F, Zhang Z, Tian Y, and Chen Y. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS, J Mass Spectrom. 2006;41, 477-486
9. Gochman N, Gantt CL. A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. J Pharmacol Exp Ther. 1962;135:312.
10. Sadee W, Dagcioglu M, Riegelman S. Fluorometric microassay for spironolactone and its metabolites biological fluids. J Pharm Sci. 1972;61:1126.
11. Overdiek JW, Hermens WA, Merkus FW. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography. J Chromatogr. 1985;341:279.
12. Sherry JH,O'Donnel JP, Colby HD. Separation of spironolactone and its biologically active sulfur-containingmetabolites by highperformance liquid chromatography. J Chromatogr. 1986;374:183.
13. Varin F, Tu TM, Benoit F, Theoret Y. High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction. J Chromatogr. 1992;574:57.
14. Jankowski A, Skorek-Jankowska A, Lamparczyk H. Simultaneous determination of spironolactone and its metabolites in human plasma. J. Pharm. Biomed. Anal. 1996;14:1359.
15. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation. 2001.